PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe.

Autor: Taskén K; Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway. kjetil.tasken@medisin.uio.no., F Haj Mohammad S; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands. s.f.haj_mohammad@lumc.nl., Fagereng GL; Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway. gfageren@ous-hf.no., Sørum Falk R; Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway. rs@ous-hf.no., Helland Å; Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. aslaug.helland@medisin.uio.no., Barjesteh van Waalwijk van Doorn-Khosrovani S; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands; CZ Health Insurance, Tilburg, The Netherlands. sahar.van.waalwijk@cz.nl., Steen Carlsson K; Swedish Institute for Health Economics, Lund, Sweden. katarina.steen_carlsson@ihe.se., Ryll B; Stockholm School of Economics Institute for Research, Stockholm, Sweden. Bettina.Ryll@hhs.se., Jalkanen K; Clinical Trial Unit, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland. katriina.jalkanen@hus.fi., Edsjö A; Department of Clinical Genetics, Pathology and Molecular Diagnostics, Region Skåne, Malmö, Sweden. anders.edsjo@skane.se., Russnes HG; Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Pathology, Oslo University Hospital, Oslo, Norway. h.e.g.russnes@medisin.uio.no., Lassen U; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. ulrik.lassen@regionh.dk., Hallersjö Hult E; Stockholm School of Economics Institute for Research, Stockholm, Sweden. ebba.hallersjo.hult@hhs.se., Lugowska I; Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland. Iwona.Lugowska@nio.gov.pl., Blay JY; Centre Léon Bérard, Lyon, France. jean-yves.blay@lyon.unicancer.fr., Verlingue L; Centre Léon Bérard, Lyon, France. Loic.VERLINGUE@lyon.unicancer.fr., Abel E; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden. edvard.abel@vgregion.se., Lowery MA; Trinity St James Cancer Institute, Trinity College, Dublin, Ireland. MLOWERY@tcd.ie., Krebs MG; Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK. matthew.krebs@nhs.net., Staal Rohrberg K; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. kristoffer.staal.rohrberg@regionh.dk., Ojamaa K; Hematology-Oncology Clinic at Tartu University Hospital, Tartu, Estonia. Kristiina.Ojamaa@kliinikum.ee., Oliveira J; Instituto Português de Oncologia do Porto FG, Porto, Portugal. julio.oliveira@ipoporto.min-saude.pt., Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. h.verheul@erasmusmc.nl., Voest EE; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. e.voest@nki.nl., Gelderblom H; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands. a.j.gelderblom@lumc.nl.

Publikováno v: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2024 May 23; Vol. 63, pp. 385-391. Date of Electronic Publication: 2024 May 23.